GlassScriptPhysician profile
Alan L Feldman
NPI 1760448179
$1,623.86
in general payments reported to CMS, 2019-2025
28 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.65 · 2020: $141 · 2021: $256 · 2022: $266 · 2023: $199 · 2024: $401 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $486.93 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.34 | 2020-2022 | |
| Glaxosmithkline, LLC. | $157.26 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $90.54 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $58.51 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $53.98 | 2020-2022 | |
| Boston Scientific Corporation | $44.99 | 2022-2025 | Watchman Flx |
| Amgen INC. | $40.96 | 2024-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $34.30 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $33.78 | 2024 | Austedo Xr |
| Abbvie INC. | $29.24 | 2021 | |
| Abbott Laboratories | $27.83 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.50 | 2024 | Caplyta |
| Eisai INC. | $24.93 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $16.61 | 2025 | Uptravi, Opsumit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.47 | 2024 | Xifaxan |
| Melinta Therapeutics, LLC | $15.45 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $15.31 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $14.67 | 2021 | |
| Viatris Specialty LLC | $14.44 | 2025 | Yupelri |
| Organogenesis INC. | $14.36 | 2025 | Puraply Wound Matrix |
| Lilly USA, LLC | $13.67 | 2025 | Zepbound, Mounjaro |
| Dexcom, INC. | $12.97 | 2021 | |
| Biodelivery Sciences International, INC. | $12.90 | 2021 | |
| Horizon Therapeutics Plc | $12.72 | 2019 | |
| Hikma Pharmaceuticals USA | $12.71 | 2023 | Ryaltris, Mitigare |
| Kowa Pharmaceuticals America, INC. | $12.54 | 2022 | |
| Amarin Pharma, INC. | $11.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.